Table 3.
Correlation of UBE2C Alteration with Clinicopathologic Parameters in CRC
| Total no. (%) | UBE2C alterations, no. (%)⁎ | No UBE2C alterations, no. (%) | P value | |
|---|---|---|---|---|
| Total no. of cases | 317 | 195 (61.5) | 122 (38.5) | |
| Age | ||||
| ≤50 years | 109 (34.4) | 65 (59.6) | 44 (40.4) | 0.6187 |
| >50 years | 208 (65.6) | 130 (62.5) | 78 (37.5) | |
| Sex | ||||
| Male | 150 (47.3) | 94 (62.7) | 56 (37.3) | 0.6893 |
| Female | 167 (52.7) | 101 (60.5) | 66 (39.5) | |
| Tumor site | ||||
| Descending colon | 263 (83.0) | 165 (62.7) | 98 (37.3) | 0.3263 |
| Ascending colon | 54 (17.0) | 30 (55.6) | 24 (44.4) | |
| Histologic type | ||||
| Adenocarcinoma | 272 (85.8) | 175 (64.3) | 97 (36.7) | 0.0122 |
| Mucinous carcinoma | 45 (14.2) | 20 (44.4) | 25 (55.6) | |
| Tumor stage | ||||
| I | 39 (13.0) | 25 (64.1) | 14 (35.9) | 0.1049 |
| II | 99 (33.0) | 52 (52.5) | 47 (47.5) | |
| III | 125 (41.7) | 81 (64.8) | 44 (35.2) | |
| IV | 37 (12.3) | 27 (73.0) | 10 (27.0) | |
| Differentiation | ||||
| Well | 25 (7.9) | 13 (52.0) | 12 (48.0) | 0.2979 |
| Moderate | 231 (72.9) | 148 (64.1) | 83 (35.9) | |
| Poor | 61 (19.2) | 34 (55.7) | 27 (44.3) | |
| Cyclin A† | ||||
| >5 | 252 (82.1) | 163 (64.7) | 89 (35.3) | 0.0175 |
| ≤5 | 55 (17.9) | 26 (47.3) | 29 (52.7) | |
| Cyclin B1† | ||||
| >5 | 270 (87.7) | 176 (64.2) | 94 (34.8) | 0.0026 |
| ≤5 | 38 (12.3) | 15 (39.5) | 23 (60.5) | |
| Ki-67† | ||||
| >50 | 266 (85.8) | 174 (65.4) | 92 (34.6) | 0.0023 |
| ≤50 | 44 (14.2) | 18 (40.9) | 26 (59.1) | |
| 5-Year overall survival | 0.0348 |
⁎
UBE2C alterations: presence of either protein overexpression and/or UBE2C gene amplification in a CRC samples.
†
Analysis failure of some IHC markers was attributed to missing or nonrepresentative spots.